Current and future landscape of poly (ADP-ribose) polymerase inhibition resistance.

ABSTRACT:

Purpose of review

To highlight relevant strategies to overcome poly(ADP-ribose) polymerase (PARP) inhibitor resistance and present key clinical trials.

Recent findings

The use of PARP inhibition (PARPi) for frontline maintenance offers substantial clinical benefit in patients with homologous recombination-deficient tumors. However, expanding PARPi from recurrent therapy to frontline maintenance may potentially result in more PARPi resistant tumors earlier in the treatment continuum and data for the use of PARPi after PARPi remain limited. Clinical evidence demonstrates tumors may develop resistance to PARPi through demethylation of the BRCA promoter or BRCA reversion mutations. Multiple clinical trials investigating therapeutic strategies to overcome resistance, such as comb

SUBMITTER: Hinchcliff E 

PROVIDER: S-EPMC7958870 | biostudies-literature | 2021 Feb

REPOSITORIES: biostudies-literature